A descriptive study of potential sight threatening event and severe visual loss following exposure to XALKORI (crizotinib) First published 29/03/2016 Last updated 23/04/2024 EU PAS number:EUPAS12963 Study Finalised
United BioSource Corporation (UBC) Switzerland First published:25/04/2013 Last updated 06/03/2024 Institution Non-Pharmaceutical company ENCePP partner